Genitrix has announced that HY-50 Vet®, a sodium hyaluronate treatment for equine joints, has now been authorised for intravenous (IV) use.
Available until now for intra-articular (IA) use only, the company says HY-50 delivers the highest concentration of sodium hyaluronate on the market for the treatment of non-infectious joint inflammation and the enhancement of joint function.
Genitrix also says that, as IV application requires less specialist preparation than IA, HY-50 is now a practical solution for mixed practices with a smaller equine case load. Injected intravenously, the product will also benefit horses with multiple joint injuries.
HY-50 is presented in a 3 ml pre-loaded syringe, delivering 50 mg of sodium hyaluronate. It costs £55.50.
Rob Watkins, Marketing Director of Genitrix, said: "The efficacy of sodium hyaluronate is well established and we're delighted to be able to offer the IV route of administration. We know it will meet a real need in the market for a lameness treatment which is proven and simple to administer."
"Perhaps most importantly, in these financially difficult times, the high concentration of the product makes it a cost-effective approach compared with competitive products. We believe it will offer an affordable treatment option for owners who are anxious to treat their horses but may be discouraged by the high cost of many treatments."
For further information, see http://www.genitrix.co.uk/ or ring 01403 786345.
Consistent with previous surveys, lameness was shown to be more likely to be caused by conditions such as osteoarthritis in the limb rather than problems in the foot.
Blue Cross carries out NEHS in May each year in partnership with the British Equine Veterinary Association (BEVA). It is sponsored by Dodson & Horrell and Zoetis and supported by the UK’s leading equestrian organisations and charities.
This year saw a 14% increase in participation compared to 2015, with survey records returned for almost 16,751 horses, ponies, donkeys and mules and 5635 people taking part. Most horses were kept in livery or a private yard and used for leisure and hacking.
Lameness has been consistently seen as the most common syndrome affecting horses in the NEHS results year on year. In the latest survey a total of 32.9% (24.4% in 2015) of horses and ponies with health problems were recorded as lame. Overall, as in previous years, lameness in the limb was more common than lameness caused by problems in the foot.
A breakdown of the types of lameness revealed that 47.4% were recorded as suffering from proximal limb lameness, 31.9% from causes of foot lameness other than laminitis and 20.7% from laminitis. Degenerative joint disease (including foot and proximal limb) was the most frequently reported single cause of lameness (41.2% of all lameness) and the most frequently reported joint affected by DJD was the hock (15.3% of all lameness).
Reports of foot lameness (excluding laminitis) more than doubled this year at 10.5% (4.5% in 2015) of all syndromes reported with pus in the foot being the most frequently recorded problem. This could possibly be attributed to the persistent wet weather during and prior to the survey, which can increase susceptibility to the condition.
Josh Slater from the Royal Veterinary College, who is a member of BEVA’s Health & Medicines Committee and analysed the NEHS data, said: "The data gleaned from the survey remains consistent year on year, confirming the reliability of our findings for benchmarking, referencing and research. This year’s increase in overall lameness may be in part attributed to the higher incidence of pus in the foot but may also be because owners are becoming more aware of lameness issues. Ongoing research on lameness has generated significant media coverage over the past year, helping to raise understanding of the importance of accurate diagnosis and treatment both from welfare and performance perspectives."
The six most notable disease syndromes identified in the 2016 National Equine Health Survey are:
Gemma Taylor, Education Officer at Blue Cross said: "The significant increase in participation again this year shows that owners and keepers of horses are really getting behind the survey and recognising its importance in safeguarding the future health and of the UK’s horses. Over the past year NEHS data has been referred to in leading equestrian and veterinary media, showing its credibility as a valuable benchmarking reference."
The 2016 NEHS survey results are now available. To download a copy visit http://www.bluecross.org.uk/nehs2016results and to register for next year’s survey please visit www.bluecross.org.uk/nehs
Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
The University of Bristol's Langford Veterinary Services (LVS) has announced the completion of its new clinical facilities.
The first phase of the £13 million development includes a new small animal surgery building, comprising five theatres, an ICU, a dedicated anaesthesia induction and recovery and an imaging suite.
The imaging suite comprises a 16-slice CT scanner, for small animals and horses, conventional digital radiography with a DR system, a high-resolution fluoroscopy, diagnostic ultrasound, echocardiography, scintigraphy and a high resolution 1.5 tesla MRI scanner available seven days a week.
Lynne Hill, Chief Executive of LVS, said: "The new facility provides state-of-the art diagnostic imaging facilities at all times, to help the animals under our care."
LVS highlights the case of Gainsborough, an eight-year-old Irish draught gelding, to illustrate the benefits of its new facilities. The horse, used for jumping and endurance, was initially presented to the Equine Hospital in October 2010, with clinical signs including nasal airflow obstruction and discharge, which was limiting his athletic capabilities.
Using videoendoscopy and radiography, a space-occupying mass was diagnosed in the paranasal sinuses impinging into the nasal cavity. With the horse conscious, but sedated, using regional local anaesthetic nerve blocks, the bulk of the mass was removed and he returned to work. However, the owner reported a recurrence of the clinical signs and he was returned to the clinic for reassessment.
The new imaging suite, only one of a few such units in the UK, has been adapted to enable the imaging of a horse's head while conscious using a frictionless air plinth. The adaptation allows detailed imaging of both bone and soft tissue structures within a horse's head, without requiring a general anaesthetic.
Using the new imaging suite, Gainsborough's CT examination revealed a portion of the mass, which had been inaccessible to the previous keyhole surgery, had expanded into the nasal cavity. The detail of the images enabled careful planning of a second operation that facilitated removal of the large remnant of the mass, which appeared to be benign, with minimal collateral trauma.
In addition to imaging the heads of conscious horses, dogs and cats are able to undergo complete body scans using the same unit while anaesthetised. As well as enabling detection and diagnosis of lesions without invasive or painful tests at an earlier stage, the unit will facilitate operative planning and add to the body of knowledge of disease pathogenesis.
For more information about LVS, visit: http://www.langfordvets.co.uk/
The campaign comprises a series of short videos featuring equine behaviourist Gemma Pearson MRCVS. The videos demonstrate quick and simple ways of teaching horses to be quiet, relaxed and safe for injections, clipping, worming, examinations and other veterinary procedures.
Equine practices can share the video links with clients here.
According to a paper published in the journal Equine Veterinary Education in January, an equine vet may expect to sustain between seven and eight work-related injuries that impede them from practicing, during a 30-year working life.1
This is far a higher figure than other civilian occupations such as the construction industry, prison service and the fire brigade.
Bruising, fracture and laceration to the leg or the head were the most common injuries reported with the main cause being a kick with a hind limb. Nearly a quarter of these reported injuries required hospital admission and 7% resulted in loss of consciousness.
David Mountford, CEO at BEVA said: "Many accidents reportedly occur when vets are trying to work with horses who have learnt to avoid examination or treatment and where handlers are not in full control. Gemma’s work at the Royal (Dick) School of Veterinary Studies and her amazing videos show how a little preparation can have a big impact on horse, owner and vet safety.”
David Catlow, Blue Cross director of clinical services, said: "These videos are a superb resource to help with behaviour training in horses and to help them remain calm and manageable in all sorts of circumstances. Time spent on behaviour training of horses, using positive reinforcement methods such as these, is time well spent for everyone’s safety. Blue Cross invests a great deal of time in behaviour training on the horses we rehome, and it works."
The seven practical videos cover how clients can train and prepare their horse for:
David Mountford added: "These videos make interesting viewing for vets as well as horse owners and build on Gemma’s eBEVA webinar "Practical Equine Behaviour" and the Guidance on Managing Equine Risks that BEVA has produced.”
You can watch the videos here.
Photo: Equine vets Malcolm Morley and Gemma Pearson
The small animal and business meeting takes place on the 2nd and 3rd October. The farm and business national meeting is on the 18th and 19th September, and the equine and business meeting is on the 9th and 10th October.
The small animal meeting will also cover other topics such as the art of conversations to dentistry, while the farm meeting will focus on team working, competitive advantage, genomics and mental resilience.
All three events include a team-based activity and a social evening which offers the chance to network and exchange experiences and ideas.
Susan Goodfellow, the Chief Marketing Officer at XLVets said: "It's fine to know what we do but to actually experience it as part of our community is quite different. We know that talking to members and being part of a group of individuals that come together to determine their own future is the best way for veterinary professionals to see what's possible and how we strive for excellence together."
XLVets is also encouraging anyone who is thinking about starting their own practice to attend the events; the company has a number of programmes designed to support prospective owners with things like finding funding, identifying the right financial set up, and acquiring the skills needed to lead a team effectively.
Susan says many vets have a strong entrepreneurial mindset but lack support or know-how to allow them to take the first step to ownership: "Locum roles and mobile set ups are often stepping stones to practice ownership but the barriers can seem significant, not to mention any personal reservations people might have about all it entails. Support from like-minded colleagues who can openly share their experiences can help to make it seem possible, desirable and achievable."
Veterinary professionals wishing to attend one of the meetings should contact Colm McGinn, Chief of Implementation, in confidence, at colm.mcginn@xlvets.co.uk or call 01228 711788.
The Animal Health Trust has presented the results of a study which has identified a significant link between hind limb lameness and saddle slip, showing consistent saddle slip in some horses with hind limb lameness, even when the lameness is fairly subtle and difficult to detect.
According to the AHT, saddle slip in sports horses is a well-recognised problem that can occur for a variety of reasons, including asymmetry in the shape of the horse's back, riders sitting crookedly and ill-fitting saddles. Sue Dyson, Head of Clinical Orthopaedics at the Centre for Equine Studies at the Animal Health Trust, had also observed that saddle slip may occur because of hind limb lameness. The intention of the study, therefore, was to find out more about the interrelationships between the horse, saddle and rider and to document the frequency of occurrence of saddle slip in horses with hind limb lameness compared with other horses.
The research was undertaken by Sue Dyson and Intern Line Greve and was presented at the British Equine Veterinary Association (BEVA) Congress last month. It is thought to be the first study of its kind, and was supported by the Saddle Research Trust (SRT). The SRT is a charitable organisation, aiming to facilitate research and provide support as well as advice on the influence of the saddle on the welfare and performance of horses and riders.
The study assessed 128 horses of varying size, age and type. The degree of lameness of each horse was graded; back shape and symmetry were measured and saddles assessed for symmetry and fit. Each horse was ridden by at least two riders and rider straightness plus weight were recorded. The grade of saddle slip, whether it occurred with more than one rider, and whether saddle slip was influenced by the direction of movement or the diagonal on which the rider was sitting were also noted.
The saddle consistently slipped to one side in 54% of horses with hind limb lameness, compared with 4% of horses with fore limb lameness, 0% with back pain and/or sacroiliac joint region pain and 0% of non-lame horses. Diagnostic analgesia was subsequently used to abolish the hind limb lameness and this eliminated the saddle slip in 97% of cases.
Sue said: "Our findings emphasise the need to educate owners, veterinarians, physiotherapists, trainers, riders and saddle fitters that saddle slip is frequently an indicator of lameness, not necessarily a manifestation of an ill-fitting saddle or asymmetric shape of the horse's back. Detection of saddle slip provides an opportunity for the owner, riders and trainers to detect low-grade and subclinical lameness, with important welfare consequences."
Further scientific studies are planned, with the support of the Saddle Research Trust, in order to build on these findings. To this end the SRT is currently seeking an honorary fundraiser to help secure ongoing financial support. For further information contact Anne Bondi on 07775 912202 or email annebondi@me.com.
1An investigation of the relationship between hindlimb lameness and saddle slip, L. Greve and S.J. Dyson, Centre for Equine Studies, Animal Health Trust, Lanwades Park, Kentford, Newmarket, Suffolk, CB8 7UU, UK.
All existing BEVA members will have their membership automatically extended until 30 June 2020. The association is also inviting vets and vet nurses who are not already BEVA members to join as online members free of charge until 30 June 2020.
BEVA President Tim Mair said: “In this extraordinary time of global crisis our profession, as with many industries, is under immense pressure. By offering free membership we are giving equine vets easy access to a wealth of supportive resources and online CPD to help them through these dark times.”
BEVA membership includes:
The association is also looking at other ways to support the profession, which has included making all BEVA Congress 2019 webinars available to members via the BEVA online learning platform.
To sign up from Monday 30 March 2020 visit: https://www.beva.org.uk/Join-BEVA
The Fédération Équestre Internationale (FEI) has added Metacam for Horses to its 'list of detection times'.
According to the manufacturer, Boehringher Ingelheim Vetmedica, Metacam (meloxicam) is the first preferential COX-2 inhibitor to be added to this list, and has stated plasma and urine detection times of 72 hours administered intravenously or orally1. This is the shortest urine detection time of the NSAIDs available for use in horses, and compares to the 168-hour (7 days) detection time for phenylbutazone stated by the FEI.
Craig Beck, equine sales and marketing manager for Boehringer Ingelheim in the UK and Ireland said: "We have been very happy to work in partnership with the FEI to provide the robust data that has supported the FEI in their analysis of Metacam. Metacam is an important addition to the FEI list, that will help vets treating competition horses. There is now a modern and proven NSAID which extends the therapeutic options available to vets."
Metacam is licensed in horses for the alleviation of inflammation and relief of pain associated with musculo-skeletal disorders or colic.
For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
1 Detection Time agreed with the European Horse Racing Scientific Liaison Committee (EHSLC)
The guidelines, which have produced by a panel of clinicians and analgesia researchers, summarise the current evidence and offer expert opinion and best practice recommendations for the use of analgesics for common scenarios.
Recommendations include:
Professor Celia Marr, Editor of the EVJ said: "The BEVA primary care clinical guidelines provide up-to-date clarity on the fundamental aspects of equine pain management for the clinician and are essential reading for all those in first opinion ambulatory roles."
The guidelines are the first in a series being produced for primary care vets by BEVA. They can be downloaded here: https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13198
Tim took over the role from Renate Weller at the end of BEVA Congress last week. Lucy Grieve, of Rossdales Veterinary Surgeons became President Elect.
After leaving Bristol in 1989, Tim worked in mixed practice before joining Bell Equine in 1993, becoming a partner in 1995. He led the hospital services at Bell Equine, as well as supervising the practice’s residency, intern and extern programmes, until it was bought by CVS in 2016. He continues to work as a clinician at Bell Equine whilst also working as the Equine Veterinary Director of CVS.
Tim is an RCVS Specialist in both equine internal medicine and equine soft tissue surgery and is a founding diplomate of the European College of Equine Internal Medicine; he became an Associate of the European College of Veterinary Diagnostic Imaging in 2011. He is an honorary Professor of the Royal Veterinary College and became a Fellow of the RCVS in 2016.
Editor of Equine Veterinary Education, the official journal of the British Equine Veterinary Association and the American Association of Equine Practitioners for the past 23 years, Tim has particular interests in clinical research, clinical standards and evidence based medicine, and has published widely in the professional veterinary literature, as well as authoring and editing several textbooks. He has been a member of the RCVS Practice Standards Group since 2012.
Tim has been chair of BEVA’s Education Committee since 2014, and says that during his presidential year he is keen to continue to develop BEVA’s educational activities for members at all stages of their careers.
In particular, he says he is particularly looking forward to supporting recent graduates in equine practice with relevant CPD and mentoring. He also hopes to advance the use of evidence-based veterinary medicine, and promote quality improvement in equine practice.
Tim said: "Equine practice is continuing to change and evolve with some rapidity. An important part of my focus will be on our Equine Veterinary Horizons Project, looking at anticipated advances over the next 10-15 years, what they will mean to individual practitioners and to practices and how we can adapt to and accommodate them to best advantage."
For further information visit www.beva.org.uk.
Elanco has announced the results of a challenge study which the company says demonstrates the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course1.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
According to Elanco, this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade2.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health, said: "Whilst no vaccine has been updated to match the current OIE recommendations, the results of this challenge study provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE have identified as being of concern."
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. Elanco says that experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly-based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine3.
References:
The new tool is part of a package that also includes posters and SMS texts to support veterinary practices in raising awareness of gastric ulcers to horse owners.
Equine Gastric Ulcer Syndrome (EGUS) is a serious and common condition and any type of horse can be at risk.1 EGUS can have a profound impact on a horse’s condition and performance and can be life threatening in foals. It is a challenging condition to diagnose as the clinical signs are often vague and not always present.1
Gastroscopy is the only method currently available for a definitive diagnosis. Of the two types of disease equine squamous gastric disease is graded on a numeric scale with 1 being the least severe and 4 being the most serious. Equine glandular gastric disease can be very varied in terms of location and type so grading this disease on a score system is no longer recommended. Instead it is now usually described in terms of location, severity and appearance.2
The new tool has been designed to help vets to map the area affected by gastric disease and record the details in an accessible format. This information, together with treatment and management recommendations, can be shared easily with the client. Posters explaining gastric ulceration have been designed to help increase awareness and understanding of EGUS amongst horse owners.
Zoetis says effective treatment usually involves a combination of management and medical treatments. UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.3 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.3,4 One syringe contains enough UlcerGold for a daily dose for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
References
The divestment is expected to be concluded in mid-2020, and Bayer intends to exit its stake in Elanco over time.
Bayer says that combining Elanco and Bayer Animal Health will create the number two animal heath company, with top three positions across a broad range of species and geographies. It also enhances Elanco’s portfolio of leading global brands and bolsters its innovation capabilities and R&D pipeline.
Jeffrey N. Simmons, president and chief executive officer of Elanco, said: "Combining Elanco’s strong relationship with veterinarians and Bayer’s leadership in retail and e-commerce will ultimately benefit all our customers. We look forward to joining our complementary portfolios and capabilities to build a fully focused animal health company, providing a sustained flow of innovation for farmers, veterinarians and pet owners."
Practices which want to buy the alternative imported vaccine will need to apply to the VMD for a Special Import Certificate (SIC).
Wholesalers have agreed to stock the alternative vaccine.
Zoetis says it acknowledges the concern and frustration this causes its customers and wants to reassure the equine community that it is working hard to resume Equip Rotavirus supply as soon as possible.
For further information, contact your Zoetis account manager or ring Zoetis HQ on 0345 300 8034.
The Animal Health Trust has cut the first sod of a new cancer centre for animals in Suffolk.
The AHT's Cancer Centre will provide all three treatment options: surgery, chemotherapy and radiotherapy, on one site. The cancer facility is being purpose-built to treat horses, dogs and cats.
Sue Murphy, Head of Clinical Cancer Treatment at the AHT, said: "Having all three treatment options on one site means that whatever the diagnosis, we will be able to offer each and every patient the very best options for their specific case. With one in four dogs and one in six cats developing cancer at some time in their life this new centre will help many more animals - from Suffolk, East Anglia and all across the UK."
The new centre will also further research into cancer. Treating animals with all types of the disease will enable the AHT's vets and scientists to expand current knowledge about cancer. This will help with the development of new ways to diagnose and treat the disease.
Vets and scientists at the AHT already work collaboratively with cancer researchers looking at the disease in humans. There are a number of links between human and animal cancers which have already been identified. It is hoped that knowledge gained from the AHT Cancer Centre may also help in the understanding of cancer in people.
The AHT hopes the building will open in summer 2012 . It is launching an appeal to raise much needed funds to equip the centre with a linear accelerator. This piece of specialist equipment works by delivering high-energy radiation beams to break cancerous tumours down while sparing the surrounding normal tissue.
The AHT Cancer Centre will be one of only six veterinary facilities in the UK to house a linear accelerator.
Sue Murphy added: "Currently, there is no way to tell which animals will, and which animals won't, develop cancer. It could happen to any animal at any time. This new centre will give more animals a fighting chance of beating the disease, enabling them to lead long and healthy lives. The fact that treatments developed to benefit our pets may also lead to improvements in the prevention and treatment of cancer in humans makes this centre all the more important.
"I would urge you to donate whatever you can to help equip the centre. Your donation, however large or small, will help many more animals beat cancer and it may also help in the fight against cancer in people."
If you would like to make a donation to the AHT Cancer Centre please visit www.aht.org.uk or telephone 01638 555648.
Alternatively you can make a £5 donation by textingVETS24 £5 to 70070
The Federation of European Equine Veterinary Associations (FEEVA) and the European Federation of Farriers Associations (EFFA) have announced that they have joined forces to promote best practice in farriery.
The initiative is the result of recognition by both organisations that equine welfare is best served with the use of only properly trained farriers, working closely with veterinary surgeons as and when needed.
The organisations say that the main aims of the new partnership include:
The President of FEEVA, Professor Josh Slater said: "We look forward to working together at European level and encouraging member associations to do the same at national level, with the primary intention of enhancing equine health through first class farriery."
Pfizer Animal Health is offering the chance to win £500 worth of CPD vouchers to UK veterinary surgeons who participate in the company's 5 minute online survey about Equine Herpes Virus (EHV).
Pfizer says the intention of the survey is to find out more about veterinary perceptions and understanding of this endemic disease and its effects on the UK's valuable equine industry. There are five multi-choice questions and the survey is available online from now until 31st May 2012. Vets who show their prowess in the skills-based section of the survey will be entered to win £500 of British Equine Veterinary Association CPD vouchers.
The survey is part of Pfizer's EHV awareness campaign to help vets encourage horse owners, yard managers, trainers and breeders to keep their horses protected from the effects of this common but often under-prioritised disease. The campaign includes the provision of information leaflets and the coordination of talks to help people, who manage horses, understand the severity of EHV and the best ways to prevent it.
According to Pfizer, the prevalence of EHV can be as high as 87.5% in the UK and latent infections in horses are frequently re-activated.1,2 The consequences can be serious, with abortion outbreaks proving to be a significant economic burden to owners, trainers and breeders.3,4 However, subclinical infections, although usually regarded as less serious, can remain unrecognised and can cause suboptimal performance in horses.
Sporadic, mild respiratory disease caused by EHV can lead to interrupted training and movement restrictions.4 Even after clinical recovery from EHV-1 or upper respiratory tract infections caused by EHV-4, some horse may develop 'poor performance syndrome'.5 These can all have serious financial repercussions on the equine industry.
To take part in the survey, visit http://www.ehvaware.com/. For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients please contact your Pfizer Account Manager.
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142. 2. Allen GP. 2002. Respiratory Infections by Equine Herpesvirus Types 1 and 4. In: P. Lekeux ed. 2002. Equine Respiratory Diseases. New York: International Veterinary Information Service. 3. Garré B et al. Vet Microbiol. 2007; 122(1-2): 43-51. 4. Lunn DP et al. J Vet Intern Med. 2009; 23(3): 450-61. 5. Slater, J. 2007. Equine Herpesvirus. In: Sellon, D. and Long, M. Equine Infectious Diseases. St Louis: Saunders. 144.
A new study published in Equine Veterinary Journal's (EVJ) in partnership with the American Association of Equine Practitioners, has shown that a wireless, inertial sensor-based system can effectively measure a horse's response to a flexion test.
The authors say that opinions on the value of flexion tests in assessing equine lameness have been divided for many years, but their research should turn what has always been regarded as a subjective process into a wholly objective one.
Flexion tests are used routinely in horses with subtle or imperceptible lameness, to exacerbate the problem and make it apparent to the observer. The test involves applying a short period of pressure to the joints of the limb before re-examination, and evaluating any change in gait. However, flexion tests rely on the ability of the observer to identify and interpret changes in the horse's gait and in that respect these tests are subjective and not necessarily consistent between observers.
The research study was conducted by orthopaedic surgeons based at the University of Glasgow's School of Veterinary Medicine1. A total of 17 healthy adult horses, all in work, were fitted with sensors before being trotted in a straight line. The sensors measured vertical pelvic movement asymmetry for both right and left hind limb strides and the average difference in maximum and minimum pelvic height between right and left hind limb strides. A hind limb was randomly selected for 60 seconds of proximal flexion, after which the horse was trotted for a minimum of 10 strides. Response to the flexion was blindly assessed as negative or positive by an experienced observer.
John Marshall, lecturer in equine surgery at the University of Glasgow, who led the study, said: "A positive response to flexion resulted in significant changes to objective measurements of pelvic symmetry, supporting the use of inertial sensor systems to objectively assess response to flexion tests."
Professor Jim Moore, North American Editor of the EVJ, said: "The introduction of an objective approach to documenting lameness examination will not only help vets and trainers to investigate equine lameness more accurately. It will also serve as an unbiased method of communicating lameness examination findings among vets, trainers, farriers and other professionals."
The next phase of research will be to establish cut-off values for objective assessment of other equine lameness diagnostic procedures, such as nerve blocks.
Reference
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
At 9.00am on Thursday and 1.45pm on Friday, Dr Sam Taylor, Feline Specialist and academy lead at the International Society of Feline Medicine (ISFM), will present ‘feline pawsative’, a talk about about cat inappetence and the remedy offered by Mirataz.
At 11.20am on Thursday and 9.00am on Friday, Matt Gurney, clinical director at Anderson Moores will be sharing the latest developments in sedation in dogs including Zenalpha.
At 12.30pm on Thursday and 12.35pm on Friday, Andrew Waller (pictured right), chief scientific officer at Intervacc AB, will be discussing how to rein in the impact of strangles using Dechra’s new protein-based vaccine, Strangvac.
The CPD sessions are first come, first served, and Dechra says it expects the presentations to be well-attended, so it could be worth getting there a little early, although probably no need to pitch a tent outside the night before.
XLEquine and the Animal Health Trust (AHT) have launched Plan, Prevent, Protect, billed as the UK's first equine biosecurity booklet for horse owners and yard managers to work through with their veterinary surgeon, to minimise disease risk on yards and maintain the health and welfare of the horses in their care.
Mark Tabachnik MRCVS, of XLEquine member practice Wright & Morten Veterinary Surgeons said: "For many yard and horse owners, biosecurity is just not on their radar. It only becomes important after they have had an outbreak! Strangles in particular can have devastating effects which impact not only on horse welfare, but the disruption and paralysis of animal movement has significant consequences with relationships on the yard, not to mention the financial costs in some cases.
"We wanted to develop a practical guide that pre-empts these issues by helping owners to set in place simple and in many cases common sense, plans and procedures to prevent a disease outbreak, along with practical steps should the worst happen, and an outbreak occurs.
"Our veterinary farm colleagues and the medical profession are well ahead in terms of biosecurity measures. It's about changing people's mind-sets. For example the NHS "Catch it Bin it Kill it" campaign has been highly successful in adapting our thoughts and actions towards disease spread, and consequently many of us are more aware of the importance of good biosecurity in one way or another."
Dr Richard Newton, Head of Epidemiology and Disease Surveillance at the AHT was also involved in the development of the booklet. He said: "I hope that this will encourage all equine practices to raise their game, it is so important for the whole equine community."
The booklet is available to all equine clients of XLEquine member practices, or it is available to view at http://www.xlequine.co.uk/content/plan-prevent-protect
Merial has announced the launch of a new Blippar app designed to educate horse owners about gastric ulcers.
By using the app - which is available free from the App Store for iPhone or Google Play for Android phones - to scan the company's Gastrogard (omeprazole) adverts, posters or website, clients can watch an educational film with one of the UK's leading specialists in equine ulcers, Richard Hepburn BVSc MS(Hons) CertEM(IntMed) DipACVIM(LA) MRCVS, American and RCVS Specialist in Equine Internal Medicine, demonstrating the signs of ulcers and diagnosis via gastroscopy.
Merial's Equine Marketing and Technical Manager Louise Radford MRCVS said: "With 60% of competition horse and 38% of leisure horses & ponies estimated to have gastric ulcers¹,²,³, it's important that horse owners are aware of the signs of this under-diagnosed condition.
"We know that the number of horses diagnosed and treated for ulcers falls significantly short of incidence levels. We hope that this app will help to raise awareness and prompt more horse owners to consult their vet about gastric ulceration."
A separate Blippar app is also available for horse owners that have been prescribed GastroGard. By scanning the pack, clients can view educational video footage on gastric ulcers, find management tips on treatment and prevention, and set a reminder for future risk periods.
For more information, visit: http://www.equinegastriculcers.co.uk, contact your local Merial equine territory specialist or call Merial Customer Support on 0870 6000123.